UNLABELLED: Hu antigen R (HuR) is a central RNA-binding protein regulating cell dedifferentiation, proliferation, and survival, which are well-established hallmarks of cancer. HuR is frequently overexpressed in tumors correlating with tumor malignancy, which is in line with a role for HuR in tumorigenesis. However, the precise mechanism leading to changes in HuR expression remains unclear. In the liver, HuR plays a crucial role in hepatocyte proliferation, differentiation, and transformation. Here, we unraveled a novel mean of regulation of HuR expression in hepatocellular carcinoma (HCC) and colon cancer. HuR levels correlate with the abundance of the oncogene, murine double minute 2 (Mdm2), in human HCC and colon cancer metastases. HuR is stabilized by Mdm2-mediated NEDDylation in at least three lysine residues, ensuring its nuclear localization and protection from degradation. CONCLUSION: This novel Mdm2/NEDD8/HuR regulatory framework is essential for the malignant transformation of tumor cells, which, in turn, unveils a novel signaling paradigm that is pharmacologically amenable for cancer therapy.
UNLABELLED: Hu antigen R (HuR) is a central RNA-binding protein regulating cell dedifferentiation, proliferation, and survival, which are well-established hallmarks of cancer. HuR is frequently overexpressed in tumors correlating with tumor malignancy, which is in line with a role for HuR in tumorigenesis. However, the precise mechanism leading to changes in HuR expression remains unclear. In the liver, HuR plays a crucial role in hepatocyte proliferation, differentiation, and transformation. Here, we unraveled a novel mean of regulation of HuR expression in hepatocellular carcinoma (HCC) and colon cancer. HuR levels correlate with the abundance of the oncogene, murine double minute 2 (Mdm2), in humanHCC and colon cancer metastases. HuR is stabilized by Mdm2-mediated NEDDylation in at least three lysine residues, ensuring its nuclear localization and protection from degradation. CONCLUSION: This novel Mdm2/NEDD8/HuR regulatory framework is essential for the malignant transformation of tumor cells, which, in turn, unveils a novel signaling paradigm that is pharmacologically amenable for cancer therapy.
Authors: Dimitris P Xirodimas; Mark K Saville; Jean-Christophe Bourdon; Ronald T Hay; David P Lane Journal: Cell Date: 2004-07-09 Impact factor: 41.582
Authors: E Medico; A M Mongiovi; J Huff; M A Jelinek; A Follenzi; G Gaudino; J T Parsons; P M Comoglio Journal: Mol Biol Cell Date: 1996-04 Impact factor: 4.138
Authors: Lin-nan Shen; Huanting Liu; Changjiang Dong; Dimitris Xirodimas; James H Naismith; Ronald T Hay Journal: EMBO J Date: 2005-03-17 Impact factor: 11.598
Authors: Rafael M Scheiba; Alain Ibáñez de Opakua; Antonio Díaz-Quintana; Isabel Cruz-Gallardo; Luis A Martínez-Cruz; María L Martínez-Chantar; Francisco J Blanco; Irene Díaz-Moreno Journal: RNA Biol Date: 2014 Impact factor: 4.652
Authors: H-S Park; U-I Ju; J-W Park; J Y Song; D H Shin; K-H Lee; L S Jeong; J Yu; H W Lee; J Y Cho; S Y Kim; S W Kim; J B Kim; K S Park; Y-S Chun Journal: Cell Death Differ Date: 2016-03-18 Impact factor: 15.828